Precision BioSciences reports ~$158M cash; DMD gene editing abstract accepted at ASGCT

PRECISION BIOSCIENCES INC

Expects ~$158M cash as of March 31, 2023; cash runway through Q1 2025.
PBGENE-DMD preclinical data selected for oral presentation at ASGCT May 2023.
ARCUS nucleases designed to excise ~500k bp mutation hot spot in dystrophin gene.
Abstract available May 2, 2023 on ASGCT website.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PRECISION BIOSCIENCES INC reported preliminary financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: preliminary results

Exact text from the filing

Although it has not finalized its full financial results for the quarter ended March 31, 2023, Precision BioSciences, Inc. (the “Company”) expects to report that it had approximately $158 million in cash and cash equivalents as of March 31, 2023.

View on SEC.gov

Browse all earnings releases →

PRECISION BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000950170-23-013169

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.